As Delta takes con­trol, US re­sumes use of Lil­ly's Covid-19 mAb com­bo na­tion­wide

A lit­tle more than two months af­ter the US halt­ed all ship­ments of Eli Lil­ly’s mon­o­clon­al an­ti­body com­bo for the treat­ment of Covid-19 on a na­tion­al ba­sis, the FDA has de­cid­ed that the use of the drug can re­sume across the coun­try.

“Based on the most cur­rent­ly avail­able da­ta, bam­lanivimab and ete­se­vimab are now au­tho­rized in all U.S. states, ter­ri­to­ries, and ju­ris­dic­tions,” the FDA said yes­ter­day, not­ing in a fact sheet that the com­bo re­tained ac­tiv­i­ty against the Delta vari­ant. The com­bo had pre­vi­ous­ly been pulled be­cause it strug­gled to work against the Be­ta and Gam­ma vari­ants, which are now no longer preva­lent in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER